Treosulfan
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Treosulfan: From Unrecorded Original Indication to Diabetic Cataract
One-Sentence Summary
Treosulfan’s original approved indication is not currently on record, and the drug is not marketed in the US. The TxGNN model predicts it may be effective for Diabetic Cataract, but this prediction is currently supported by 0 clinical trials and 0 publications — score-only evidence from the knowledge graph embedding.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on record (no licenses or indication data available) |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 99.01% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for treosulfan, and no original indication is on record in this evidence pack — the drug is not marketed in the US and has no license history to draw from.
Because both the original indication and MOA are unknown, no mechanistic or pharmacological pathway can currently be established linking treosulfan to diabetic cataract. This predicted indication comes solely from the TxGNN knowledge-graph embedding’s high similarity score (0.99), without any supporting biological rationale, clinical trial, or literature evidence at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate is at the earliest evaluation stage (S0) with L5 evidence — a model-only prediction lacking MOA data, original indication history, market status, and any clinical trial or literature support. There is currently insufficient basis to advance.
To proceed, the following is needed:
- TFDA package insert / warnings and contraindications (blocking gap — required before any safety pre-screening can begin)
- Mechanism of action (MOA) data from DrugBank, to assess biological plausibility for diabetic cataract
- Confirmation of treosulfan’s original approved indication(s)
- Emerging clinical trial or literature evidence specific to diabetic cataract, to move beyond model-only prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.